teroxirone and Vomiting

teroxirone has been researched along with Vomiting* in 2 studies

Other Studies

2 other study(ies) available for teroxirone and Vomiting

ArticleYear
Phase-I study of alpha-1,3,5-triglycidyl-s-triazinetrione (NSC 296934).
    Cancer chemotherapy and pharmacology, 1983, Volume: 11, Issue:1

    alpha-1,3,5-Triglycidyl-s-triazinetrione (TGT) is a triepoxide derivative with alkylating properties discovered by random screening. TGT has been found to be active against a wide variety of murine tumors, including a P388 subline resistant to cyclophosphamide. The starting dose in this phase-I study was 30 mg/m2 as a single dose IV, repeated every 3-4 weeks, increasing up to 2,700 mg/m2. Severe dose-limiting toxicity took the form of phlebitis becoming apparent a few days after treatment. This was initially seen at the 480 mg/m2 dose level, and was observed with increasing frequency and intensity at higher dose levels. Leukopenia occurred regularly at dose levels above 1,800 mg/m2 and resulted in life-threatening leukopenia in one patient, and in a toxic death at 2,700 mg/m2 in another patient. Other toxic side-effects included moderate reversible thrombocytopenia, nausea, and vomiting. It is recommended that further trials with TGT await the development of more water-soluble formulations or of other triepoxide derivatives.

    Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Triazines; Vomiting

1983
Phase I clinical trial with alpha 1,3,5- triglycidyl-s-triazinetrione (NSC-296934).
    European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:12

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Infusions, Parenteral; Leukopenia; Male; Middle Aged; Nausea; Neoplasms; Thrombophlebitis; Triazines; Vomiting

1981